Stocktoria
Airsculpt Technologies, Inc. AIRS
Airsculpt Technologies, Inc. (AIRS) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 0.08% (safety: no dividend). FY2025 revenue was $151.8M at a -7.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.066 |
| Retained earnings / assets | -0.217 |
| EBIT / assets | -0.062 |
| Equity / liabilities | 0.881 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AIRS | Airsculpt Technologies, Inc. | 3/9 | -0.63 | — | -15.8% |
| SBC | SBC Medical Group Holdings Inc | 3/9 | 8.55 | 6.7 | -15.5% |
| LFMD | LifeMD, Inc. | 5/9 | -9.85 | 13.9 | +25.3% |
| CCM | Concord Medical Services Holdings Ltd | 6/9 | -3.98 | — | +25.2% |
| TOI | Oncology Institute, Inc. | 4/9 | -5.27 | — | +27.8% |
| HIMS | Hims & Hers Health, Inc. | 4/9 | 1.61 | 61.2 | +59% |
| TDOC | Teladoc Health, Inc. | 5/9 | -16.73 | — | -1.5% |
About Airsculpt Technologies, Inc.
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States and Canada. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient's own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company's body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. The company was founded in 2012 and is headquartered in Miami Beach, Florida.
FAQ
Is AIRS financially healthy?
Airsculpt Technologies, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does AIRS pay a dividend, and is it safe?
Yes. Airsculpt Technologies, Inc. pays a dividend yielding about 0.08% with a None payout ratio, rated “no dividend” for safety.
How profitable is AIRS?
In FY2025, Airsculpt Technologies, Inc. had a net margin of -7.7% and a return on equity of -13.3%.
What is the analyst price target for AIRS?
The average Wall-Street price target for Airsculpt Technologies, Inc. is $4.50, about 38.5% above the recent price, from 1 analysts.
Is AIRS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Airsculpt Technologies, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone, a dividend yield of 0.08%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.